HS
ADAP

HighVista Strategies’s Adaptimmune Therapeutics ADAP Stock Holding History

HighVista Strategies’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-159,351
Closed -$859K – 126
2020
Q4 		$859K Buy
159,351
+103,872
+187% +$564K 0.55% 39
2020
Q3 		$443K Buy
+55,479
New +$486K 0.32% 61

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HighVista Strategies's ADAP Position: Q1 2021 in Review

HighVista Strategies sold out of Adaptimmune Therapeutics (ADAP) in Q1 2021, closing a stake of 159,351 shares — an estimated $859K sold.

HighVista Strategies first reported a position in ADAP in Q3 2020 and held it in 2 quarters. The position peaked at $859K in Q4 2020. 84 funds tracked by Wall St. Rank hold ADAP as of Q1 2021.

  • HighVista Strategies reported no remaining Adaptimmune Therapeutics position as of Q1 2021 after selling out during the quarter.
  • HighVista Strategies sold 159,351 Adaptimmune Therapeutics shares in Q1 2021, an estimated $859K.
  • HighVista Strategies first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 2 quarters.
  • HighVista Strategies's Adaptimmune Therapeutics position peaked at $859K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2021.

Based on HighVista Strategies's 13F filing for Q1 2021, filed 17 May 2021.